



Characterization and biodistribution of bevacizumab TPGS-based nanomicelles: Preliminary studies



Fiorella Tesan^a, Cristal Cerqueira-Coutinho^b, Jimena Salgueiro^a,
Marta de Souza Albernaz^c, Suyenne Rocha Pinto^d, Sara Rhaissa Rezende Dos Reis^d,
Emerson Soares Bernardes^e, Diego Chiapetta^{f,g}, Marcela Zubillaga^{a,f},
Ralph Santos-Oliveira^{d,*}

^a Laboratorio de Radioisótopos, Cátedra de Física, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina

^b Institute of Macromolecules, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

^c Federal University of Rio de Janeiro, University Hospital Clementino Fraga Filho, Rio de Janeiro, Brazil

^d Zona Oeste State University, Laboratory of Radiopharmacy and Nanoradiopharmaceuticals, Brazil

^e Nuclear Energy Research Institute, Radiopharmacy Center, São Paulo, Brazil

^f Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina

^g Cátedra de Tecnología Farmacéutica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina

ARTICLE INFO

Article history:

Received 28 March 2016

Received in revised form

8 September 2016

Accepted 29 September 2016

Available online 30 September 2016

Keywords:

TPGS

Bevacizumab

MKN45

Biodistribution

Nanomicelles

ABSTRACT

Bevacizumab is an FDA approved monoclonal antibody (anti VEGF) indicated in many cancers, mostly metastatic ones. D- α -tocopheryl polyethylene glycol succinate (TPGS) is the water-soluble form of vitamin E which usually forms micelles. This work aims to report preliminary results of the bio-distribution of a TPGS based nano-micelle delivery system for bevacizumab in a gastric cancer xenograft model. Evaluation of the biodistribution of micelles/bevacizumab-99mTc was performed in Balb/c nude mice carrying MKN45 cell line xenograft. The nano-radiopharmaceutical (3.7 MBq/0.2 mL) was administered intraocularly and biodistribution was assessed 1 h post administration. The activity in each organ and blood was determined by a gamma counter. Mean size was 10 ± 1 nm for pure TPGS and 11 ± 1 nm for bevacizumab-TPGS respectively. Biodistribution showed that the highest uptake was found in both lungs and liver. Kidneys had also an important uptake. The tumor accumulated moderate to low radiolabeled nanomicelles, nevertheless tumor/blood ratio was very high.

These preliminary results may help as a start point to continue evaluating the potential of radiolabeled bevacizumab-TPGS based nanomicelles to be used as a theranostic agent.

© 2016 Elsevier B.V. All rights reserved.

1. Introduction

Cancer remains one of the most severe life threatening diseases worldwide. The new cases around the world will rise to about 22 million in the next 15 years according to the World Health Organization and Cancer UK research organization [1,2]. From cancer-related deaths, gastric cancer is the third most common cause with carcinoma being the most frequent malignancy [1,3].

Scientific research has made some significant advances in detecting molecules that are highly expressed in tumors or

implicated in their growth or progression. This has led to the development of specific strategies to target malignant tissue such as the use of monoclonal antibodies [4,5]. Moreover, the incorporation of specific molecules into nano-sized delivery systems rises as an interesting and effective strategy for cancer therapy [6,7].

Bevacizumab is an FDA (Food and Drug Administration) approved monoclonal antibody that reacts against the Vascular Endothelial Growth Factor (VEGF) and is indicated in many cancers, mostly metastatic ones: first-line treatment of metastatic colorectal cancer and of non-small cell lung cancer; second-line treatment of metastatic colorectal cancer and of glioblastoma; metastatic renal cell carcinoma; metastatic Her2-negative breast cancer; metastatic colorectal cancer in combination with fluoropyrimidine-based chemotherapy; persistent, recurrent, or metastatic cervical cancer

* Corresponding author. Av. Manuel Caldeira de Alvarenga, 1203 - Campo Grande, Rio de Janeiro - RJ, 23070-200, Brazil.

E-mail address: presidenciaradiofarmacia@gmail.com (R. Santos-Oliveira).

in combination with chemotherapy and platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with chemotherapy [8].

Moreover, bevacizumab is being used for the treatment of different pathologies and other types of cancer such as gastric cancer as a combined first line treatment and several biomarkers are being proposed to predict its efficacy [9–12].

D- α -tocopheryl polyethylene glycol succinate (TPGS) is the water-soluble form of vitamin E, resulting from its esterification with polyethylene glycol 1000. Given that it is an amphiphilic compound, it usually forms micelles. Micelles are one of the nano sized particles that can act as drug delivery systems which are particularly useful in oncology given that tumor uptake might be favored by the Enhanced Permeability and Retention effect [17]. TPGS is a Generally Regarded As Safe (GRAS) listed oral supplement which has been approved by the FDA as a safe pharmaceutical adjuvant used in drug formulation and has been investigated for oral and parenteral administration in antineoplastic therapy [13–16].

Delivery of bevacizumab to specific sites of a tumor would enhance its efficacy while ameliorate its adverse effects. Therefore this work aims to report preliminary results of the biodistribution of a TPGS based nano-micelle delivery system for bevacizumab in a gastric cancer xenograft model.

2. Materials and methods

2.1. Nano-micelles preparation

For empty micelles, TPGS (Eastman Chemical Company, USA) was weighted and dissolved in distilled water (10% w/v) with continuous agitation and temperature (30 °C) until a homogeneous dispersion was achieved. After reaching room temperature the solution was used to perform the radiolabeling procedure.

For micelles carrying bevacizumab, antibody (Avastin®) was added to the TPGS dissolving solution while micelles were forming. Bevacizumab concentration in final solution was 2,5 mg/mL.

2.2. Size determination by DLS

Nanoparticles size distribution, mean size and polydispersity index (PDI) of the micelle/bevacizumab nano-system were determined by dynamic light scattering (DLS) using the equipment Zetasizer Nano ZS (Malvern Instruments, UK). Measurements were performed in triplicate at 25 °C and the laser incidence angle in relation to the sample was 173° using a 12 mm² quartz cuvette. The mean \pm standard deviation (SD) was assessed.

2.3. Tumor xenograft models

MKN45 cells (American Type Culture Collection, Manassas, VALLC) were cultured in RPMI (Gibco, Life technologies, MD, USA) supplemented with 10% of fetal bovine serum (Gibco, Life technologies, MD, USA) and 50 μ g/mL of gentamicin (Gibco, Life technologies, MD, USA). Mycoplasma contamination in cultured cells was excluded using Lonza Mycoplasma Detection Kit. For tumor induction, eight-week-old male Balb/c nude mice were implanted subcutaneously with 2×10^6 MKN45 cells and growth was accompanied for 3 weeks. Balb/c nude mice were bred at the animal facility of the Nuclear Energy Research Institute (IPEN) and all experiments were carried out in accordance with EC Directive 86/609/EEC for animal experiments and were approved by local animal ethics committees.

2.4. Labeling process

The method used was the direct labeling process as described previously [18,19]. The labeling process used 150 μ L of micelle/bevacizumab nanosystem, which were incubated with stannous chloride (SnCl₂) solution (30 μ L/mL) (Sigma-Aldrich) for 20 min at room temperature. Then, this solution was incubated with 2 mCi (approximately 300 μ L) of technetium-99m (IPEN/CNEN) for 10 min, which labeled the nanomicelles with Tc-99m.

In order to characterize the labeled micelle-bevacizumab nanosystem, thin layer chromatography (TLC) was performed using Whatman paper No 1. The chromatography was carried out by using 2 μ L of the labeled-nanomicelles in acetone (Sigma-Aldrich) as mobile phase. The radioactivity of the strips was measured in a gamma counter (Perkin Elmer Wizard® 2470). In order to confirm the efficacy of the labeling process, the chromatography was performed in 2 different times (0 and 3 h).

2.5. Biodistribution

Evaluation of the biodistribution of micelles/bevacizumab-99mTc was performed in 2 Balb/c nude mice which were induced with the tumor (as previously described) and anaesthetized with 10% Ketamine and 2% Xylazine in 15 μ L administered intramuscularly (thigh). The nano-radiopharmaceutical (3.7 MBq/0.2 mL) was administered intraocularly [20]. One hour post administration mice were sacrificed in a carbon dioxide gas chamber and the organs of interest were excised and weighed. The activity in each organ and blood was determined by a gamma counter (Perkin Elmer Wizard® 2470). Results were expressed as injected dose normalized by tissue weight (% ID/g) and as a ratio between the organ and blood pool (tissue/blood) [18]. The following organs were evaluated: brain, right lung, left lung, stomach, spleen, small intestine, large intestine, heart, right kidney, left kidney and liver. Tumor (lesion) uptake was measured as well.

3. Results

Some characteristics of the bevacizumab TPGS based nanomicelles were assessed in vitro. Radiochemical purity resulted higher than 95% at initial time and remained the same post 3 h. Fig. 1 shows size distribution of bevacizumab-TPGS based nanomicelles. Mean size was 10 ± 1 nm for pure TPGS and 11 ± 1 nm for bevacizumab-TPGS. They also presented narrow size distribution and low PDI of 0.22 ± 0.02 and 0.20 ± 0.01 respectively. It is worth mentioning that no statistical differences in size were found when




Fig. 1. Size distribution of bevacizumab TPGS-based micelles.

Download English Version:

<https://daneshyari.com/en/article/5548251>

Download Persian Version:

<https://daneshyari.com/article/5548251>

[Daneshyari.com](https://daneshyari.com)